Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-γ or IL-4, but not IL-6

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3650-3657

  Griffin, K F ^a   Eyles, J E ^a   Spiers, I D ^b   Alpar, H O ^c   Williamson, E D ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Interferon gamma; Interleukin 4; Interleukin 6; PLLA microspheres; V antigen; Yersinia pestis

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; INTERLEUKIN 4; INTERLEUKIN 6; MICROSPHERE; RECOMBINANT ANTIGEN; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LCRV PROTEIN, YERSINIA; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEIN; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENCAPSULATION; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; TREATMENT OUTCOME; YERSINIA PESTIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CHEMISTRY; DRUG FORMULATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG DISEASE; LUNG LAVAGE; METHODOLOGY; MICROBIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BRONCHOALVEOLAR LAVAGE FLUID; DRUG COMPOUNDING; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; INTERFERON TYPE II; INTERLEUKIN-4; INTERLEUKIN-6; LUNG DISEASES; MICE; MICE, INBRED BALB C; MICROSPHERES; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; TREATMENT OUTCOME; VACCINES, SYNTHETIC; YERSINIA PESTIS;

EID: 0036840780     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00396-1     Document Type: Article

References (28)

1. Meyer K.F. Effectiveness of live or killed plague vaccines in man. Bull. WHO. 42:1970;653-666.
2. Williamson E.D., Eley S.M., Griffin K.F.et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol. Med. Microbiol. 12:1995;223-230.
3. Leary S.E.C., Griffin K.F., Garmory H.S.et al. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb. Pathog. 23:1997;167-179.
4. Williamson E.D., Sharp G.J.E., Eley S.M.et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine. 14:1996;1613-1619.
5. Williamson E.D., Vesey P.M., Gillhespy K.J.et al. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin. Exp. Immunol. 116:1999;107-114.
6. Cornelis G.R., Boland A., Boyd A.P.et al. The virulence plasmid of Yersinia, an antihost genome. Microbiol. Molec. Bio. Rev. 62:1998;1315-1352.
7. Leary S.E.C., Williamson E.D., Griffin K.F.et al. Active immunisation with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 63:1995;2854-2858.
8. Anderson G.W., Leary S.E.C., Williamson E.D.et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect. Immun. 64:1996;4580-4585.
9. Williamson E.D., Eley S.M., Stagg A.J.et al. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine. 15:1997;1079-1084.
10. Eyles J.E., Williamson E.D., Spiers I.D.et al. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J. Control. Release. 63:2000;191-200.
11. Dong P., Brunn C., Ho R.J.Y.et al. Cytokines as vaccine adjuvants. Pharm. Biotechnol. 6:1995;625-643.
12. Hughes H.P. Cytokine adjuvants: lessons from the past - guidelines for the future? Vet. Immunol. Immunopathol. 63:1998;131-138.
13. Lin R., Tarr P.E., Jones T.C. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 21:1995;1439-1449.
14. Boehm U., Klamp T., Groot M.et al. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:1997;749-795.
15. Lim Y.S., Kang B.Y., Kim E.J.et al. Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-gamma-hybrid construct. Immunology. 94:1998;135-141.
16. Playfair J.H.L., DeSouza J.B. Recombinant gamma interferon is a potent adjuvant for a murine malaria vaccine in mice. Clin. Exp. Immunol. 67:1987;5.
17. Anderson K.P., Fennie E.H., Yilma T. Enhancement of a secondary antibody response to vesicular stomatitis virus "G" protein by IFN-gamma treatment at primary immunisation. J. Immunol. 140:1988;3599-3604.
18. Heath A.W., Playfair J.H.L. Conjugation of interferon-gamma to antigen enhances its adjuvanticity. Immunology. 71:1990;454-456.
19. Lachman L.B., Ozpolat B., Rao X. Cytokine containing liposomes as vaccine adjuvants. Eur. Cytokine Network. 7:1996;693-698.
20. Griffin K.F., Conway B.R., Alpar H.O.et al. Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-γ: effect of dose and formulation. Vaccine. 16:1998;517-521.
21. Cao M., Sasaki O., Yamada A.et al. Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine. 10:1992;238-242.
22. Mosmann P.D., Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145-173.
23. Hirano T., Yasukawa K., Harada H.et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 324:1986;73-76.
24. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 258:1992;593-597.
25. Ershler W.B., Sun W.H., Binkley N. The role of interleukin-6 in certain age-related diseases. Drugs Aging. 5:1994;358-365.
26. Husband A.J., Kramer D.R., Bao S.et al. Regulation of mucosal IgA responses in vivo: cytokines and adjuvants. Vet. Immunol. Immunopathol. 54:1996;179-186.
27. Beck L.R., Cowsar D.R., Lewis D.H.et al. A new long-acting microcapsule system for administration of progesterone. Fertil. Steril. 31:1979;545-551.
28. Russell P., Eley S.M., Hibbs S.E.et al. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine. 13:1995;1551-1556.